Fullerton Health shareholder spat clouds US$1 billion sale
Add BT as a preferred source
A BITTER feud among three friends-turned-foes - all shareholders and co-founders of Fullerton Healthcare Corp (Fullerton Health) - could imperil the months-long sale process of the Asian healthcare solutions firm, including last week's sweetened non-binding offer by Beverly-Hills private equity firm Platinum Equity for the Singapore-headquartered firm.
Ties over the past year or so have frayed between David Sin of SIN Capital, which majority-owns Fullerton Health, and his long-time doctor-colleagues-turned pals Michael Tan and Daniel Chan, the firm's minority shareholders and executive directors.
An early sign of the enmity emerged at the end of 2019, when Dr Tan and Dr Chan stepped down as the medical-services firm's chief executive officer (CEO) and deputy CEO respectively. Following a search for an executive CEO, Ho Kuen Loon was appointed Fullerton Health's group CEO in Jan 2020.
TRENDING NOW
Malaysian tycoon Vincent Tan’s sell-downs point to pruning rather than an exit plan
Simba ordered to pay S$700,000 in damages to indoor skydiving operator Altitude Xperience for trespass
What’s wrong with Orchard Road? Experts weigh in on the street’s cachet and its future
As luxury retail goes big, can Singapore’s Orchard Road keep up?
